Vcanbio Cell & Gene Engineering Corp., Ltd (SHSE:600645) agreed to acquire additional 3% stake in Heyuan Biological Technology (Tianjin) Co., Ltd. from Beijing Fuyuan Zhiyuan Biotechnology Partnership (Limited Partnership) on September 28, 2023. The deal value consists of CNY 37.5 million, plus some additional payment. As of June 30, 2023, Heyuan Biological Technology (Tianjin) Co., Ltd reported total assets of CNY 3.9 trillion and CNY 1.4 trillion.

The deal has been approved by board of directors of Vcanbio Cell & Gene Engineering Corp., Ltd.